Merck Global Health Innovation Fund — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
PreciseDx develops molecular pathology diagnostic tools for cancer care, combining anatomical pathology with molecular and systems biology to enable precise diagnosis and treatment planning.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesNew York, US
Dr. Carlos Cordon-Cardo(Founder)Eric Converse(Chief Executive Officer and Director)inEdward Joseph Sitar(Chief Financial Officer)Wayne Brinster(Chief Executive Officer and Director)in
BoardErik Lium(Director)Westley Dupray(Director)
Co-investorsPhilips Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.